Abstracts tagged "Elderly"

Abstract Number: 56 • 2019 ACR/ARP Annual Meeting
Choline Metabolite Is Associated with Inflammation in Arthritis in the Elderly
francesca cedola¹, Roxana Coras ², Elsa Sanchez-Lopez ³, Lourdes Mateo ⁴, Anders Pedersen ⁵, Anahy Brandy-Garcia ⁴, Águeda Prior-Español ⁴, Brin S rosenthal ⁶, Melania Martínez-Morillo ⁴ and Monica Guma ⁷, ¹University of California San Diego, Rome, Italy, ². Department of Medicine, School of Medicine. University of California, San Diego, ³Department of Pharmacology, University of California San Diego, La Jolla, San Diego, ⁴Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁵University of Gothenburg, Gothenburg, Sweden, ⁶University of California San Diego, san diego, ⁷Department of Medicine, School of Medicine. University of California San Diego, La Jolla, United States
Background/Purpose: Elderly-onset RA (EORA) and polymyalgia rheumatica (PMR) are common rheumatic disease in the elderly and their pathogenesis are still not completely understood. Perturbations caused…
Abstract Number: 325 • 2019 ACR/ARP Annual Meeting
Frailty and Sarcopenia in Inflammatory Rheumatic Disease
Elisa Trujillo¹, Antonio Aznar ², Hiurma Sanchez ¹, Marta Hernandez ¹, Alicia García ³ and Maria del mar Trujillo Martin ⁴, ¹Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ²Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ³Hospital Universitario de Canarias, Santa cruz de Tenerife, ⁴Servicio de Evaluación y Planificación, Fundación Canaria de Investigación Sanitaria (FUNCANIS) Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC)., Santa Cruz de Tenerife, Spain
Background/Purpose: Sarcopenia, the loss of skeletal muscle mass, is associated with adverse individual physical and metabolic changes contributing to morbidity and mortality. Sarcopenia is a…
Abstract Number: 1345 • 2019 ACR/ARP Annual Meeting
Are There Differences in Efficacy and Safety of Biological Disease-modifying Antirheumatic Drugs Between Elderly-onset and Young-onset Rheumatoid Arthritis?
Sadao Jinno¹, Akira Onishi ², Kengo Akashi ², Motomu Hashimoto ³, Wataru Yamamoto ³, Koichi Murata ³, Tohru Takeuchi ⁴, Takuya Kotani ⁴, Yuichi Maeda ⁵, Kosuke Ebina ⁶, Yonsu Son ⁷, Hideki Amuro ⁷, Ryota Hara ⁸, Masanori Katayama ⁹, Jun Saegusa ² and Akio Morinobu ², ¹Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Osaka, Japan, ²Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ³Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁴Department of Internal Medicine IV, Osaka Medical College, Osaka, Japan, ⁵Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan, ⁶Department of Musculoskeletal Regenerative Medicine, Osaka University, Graduate School of Medicine, Osaka, Japan, ⁷First Department of Internal Medicine, Kansai Medical University, Osaka, Japan, ⁸The Center for Rheumatic Disease, Department of Orthopedic Surgery, Nara Medical University, Nara, Japan, ⁹Department of Rheumatology, Osaka Red Cross Hospital, Osaka, Japan
Background/Purpose: To compare efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) between elderly-onset rheumatoid arthritis (EORA) and young-onset rheumatoid arthritis (YORA) patients. Methods: Patients with…
Abstract Number: 2165 • 2019 ACR/ARP Annual Meeting
Stakeholder Feedback on Novel Behavioral Intervention Targeting Comorbid Chronic Back Pain and Depression in Older Adults
Ailing Yang¹, Wei Yuet ², LaDonna Saxon ³, James LePage ³, Liana Fraenkel ⁴, Manney Reid ⁵ and Una Makris ⁶, ¹UT Southwestern Medical Center, Dallas, ²UNT Health Science Center, Fort Worth, ³Dallas VA Medical Center and UT Southwestern Medical Center, Dallas, ⁴Yale School of Medicine and VA Connecticut Healthcare System, New Haven, ⁵Weill Cornell Medicine, New York City, ⁶UT Southwestern Medical Center and Dallas VA Medical Center, Dallas
Background/Purpose: Chronic low back pain (cLBP) is the 2nd most common reason for physician visits; annual related costs exceed $100 billion and are expected to…
Abstract Number: 2170 • 2019 ACR/ARP Annual Meeting
Risk Factors for Poor Outcomes After Hip Fracture Patients in the Robust Elderly: Are Patient Reported Outcomes Important?
Lisa Mandl¹, Dina Sheira ², Marianna Frey ³, Jackie Finik ², Kirsten Grueter ³ and Joseph Lane ⁴, ¹Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, New York, NY, ²Hospital for Special Surgery, New York, NY, New York, NY, ³Hospital for Special Surgery, New York, NY, New York, ⁴Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, New York
Background/Purpose: Low energy hip fractures are feared harbingers of morbidity and mortality. However, many older adults are high functioning and cognitively intact at the time…
Abstract Number: 2392 • 2019 ACR/ARP Annual Meeting
The Effectiveness of anti-IL-6 Therapy to Elderly-onset Rheumatoid Arthritis
Takayasu Ando¹, Takeshi Suzuki ², Yutaka Gotou ¹ and Kimito Kawahata ³, ¹Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan, ²Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ³Rheumatology and Allergology, St. Marianna University School of Medicine, Tokyo, Japan
Background/Purpose: In daily practice, our rheumatologist has experienced different clinical feature of elderly-onset rheumatoid arthritis (EORA) compared with younger-onset RA (YORA). In EORA patients, serological…
Abstract Number: 1133 • 2018 ACR/ARHP Annual Meeting
Factors for Opioids Use in the Early Treatment Options for the Knee Osteoarthritis Patients
Soo-Kyung Cho¹, Seongmi Choi², Seul Gi Im², Hyoungyoung Kim¹, Sun-Young Jung³, Eun Jin Jang⁴ and Yoon-Kyoung Sung⁵, ¹Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ²Statistics, Kyungpook National University, Daegu, Korea, Republic of (South), ³College of Pharmacy, Chung-Ang University, Seoul, Korea, Republic of (South), ⁴Information Statistics, Andong National University, Andong-si, Korea, Republic of (South), ⁵Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South)
Background/Purpose: Current guidelines for osteoarthritis (OA) treatment recommend a range of nonpharmacological and pharmacological interventions to alleviate pain, improve function and quality of life. Most…
Abstract Number: 1475 • 2018 ACR/ARHP Annual Meeting
Eicosanoid Mediators of Systemic Inflammation and Arthritis in the Elderly
Roxana Coras^1,2, Rekha Narasimhan¹, Arthur Kavanaugh³, Lourdes Mateo⁴, Oswald Quehenberger⁵, Melania Martinez-Morillo⁶ and Monica Guma^1,2, ¹Medicine, University of California San Diego, La Jolla, CA, ²Medicine, Autonomous University of Barcelona, Bellatera, Spain, ³University of California, San Diego, School of Medicine, La Jolla, CA, ⁴Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁵Pharmacology, Medicine, University of California San Diego, La Jolla, CA, ⁶Rheumatology, Germans Trias i Pujol University Hospital, Barcelona, Spain
Background/Purpose: Elderly-onset RA, EORA, which is defined as rheumatoid arthritis (RA) starting at >60 years of age, has received less attention than young-onset RA. Polymyalgia rheumatica (PMR) is…
Abstract Number: 1543 • 2018 ACR/ARHP Annual Meeting
The Efficacy, Safety and Adherence of Biologicbiological Disease-Modifying Anti Rheumatic Drugs, Infliximab, Tocilizumab and Abatacept, in Elderly Patients with Rheumatoid Arthritis
Takuma Tsuzuki Wada¹, Yu Funakubo Asanuma², Mayumi Matsuda³, Hiroaki Yazawa², Yoshinobu Nakao⁴, Noritsune Kozu⁵ and Toshihide Mimura², ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine,, Saitama Medical University, Saitama, Japan, ²Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ³Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan, ⁴Department of Rheumatology, Saga University Hospital, Saga, Japan, ⁵Kozu Orthopedic Clinic, Yachiyo, Japan
Background/Purpose: Elderly patients with rheumatoid arthritis (RA) have declined physical performances and increased various complications. We are concerned about decrease of efficacy and increase of…
Abstract Number: 2176 • 2018 ACR/ARHP Annual Meeting
The Association of Gout with Incident Giant Cell Arteritis in Older Adults
Jasvinder A. Singh and John Cleveland, Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Giant cell arteritis (GCA) is a vasculitis that affects large and medium sized arteries in people 50 years or older. Gout, the most common…
Abstract Number: 2226 • 2018 ACR/ARHP Annual Meeting
Gout and the Risk of Incident Dementia in the Elderly: A Medicare Claims Study
Jasvinder A. Singh¹ and John Cleveland², ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The pursuit of a link between gout/hyperuricemia and dementia has led to contradictory results. Most observational studies, including population-based studies, showed that hyperuricemia was…
Abstract Number: 2324 • 2018 ACR/ARHP Annual Meeting
Predictors of Refracture in Patients with Hip Fragility Fracture
Sara Ganhão^1,2, Miguel Guerra³, Francisca Aguiar^1,2, Georgina Terroso¹, Romana Vieira³, Diana Gonçalves⁴, Teresa Martins-Rocha^2,5, Raquel Ferreira^1,2, Ana Águeda^2,6, Tiago Meirinhos⁷, Eva Mariz^1,2, Raquel Lucas⁸, Miguel Bernardes^1,2, Carlos Vaz^1,2 and Lúcia Costa¹, ¹Rheumatology, Centro Hospitalar de São João, Oporto, Portugal, ²Faculty of Medicine, Oporto University, Oporto, Portugal, ³Rheumatology, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal, ⁴Rheumatology, Centro Hospitalar de Trás-os-Montes e Alto Douro, Vila Real, Portugal, ⁵Rheumatology Department, Centro Hospitalar de São João, Porto, Portugal, Oporto, Portugal, ⁶Rheumatology, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, ⁷Serviço de Reumatologia, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, Aveiro, Portugal, ⁸Public Health, Centro Hospitalar de São João, Oporto, Portugal
Background/Purpose: Hip fractures are associated with substantially elevated morbidity and mortality and thus represent a serious public health problem. The purpose of this study is…
Abstract Number: 226 • 2018 ACR/ARHP Annual Meeting
Representation of Elderly People and Women in Rheumatoid Arthritis and Osteoarthritis Trials: A Systematic Review and Meta-Analysis Comparing Clinical Trials with Population-Based Studies
Andriko Palmowski¹, Thomas Buttgereit^1,2, Yannick Palmowski³, Sabrina Mai Nielsen^4,5, Maarten Boers⁶, Robin Christensen^4,5 and Frank Buttgereit¹, ¹Department of Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany, ²Department of Dermatology, Venerology and Allergology, Charité – University Medicine Berlin, Berlin, Germany, ³Center for Musculoskeletal Surgery, Charité – University Medicine Berlin, Berlin, Germany, ⁴Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg, Denmark, ⁵Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁶Department of Epidemiology and Biostatistics, and Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Elderly people (as commonly defined by an age of ≥65 years) and women have been reported to be underrepresented in clinical trials of various…
Abstract Number: 387 • 2018 ACR/ARHP Annual Meeting
Increased Risk of Malignancy in Elderly Patients with Inflammatory Myositis
Hyoungyoung Kim¹, Yoon-Kyoung Sung², Seongmi Choi³, Jinwook Kim⁴, Sun-Young Jung⁵, Eun Jin Jang⁶, Dae-Hyun Yoo⁷ and Soo-Kyung Cho¹, ¹Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ²Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ³Statistics, Kyungpook National University, Daegu, Korea, Republic of (South), ⁴Department of Statistics, Kyungpook National University, Daegu, Korea, Republic of (South), ⁵College of Pharmacy, Chung-Ang University, Seoul, Korea, Republic of (South), ⁶Information Statistics, Andong National University, Andong-si, Korea, Republic of (South), ⁷Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South)
Background/Purpose: The association between inflammatory myositis and malignancy is well established, however, the risk of malignancy in aged patients is known to be similar with…
Abstract Number: 417 • 2018 ACR/ARHP Annual Meeting
Patient Reported Outcomes Pre and Post Intervention in Older Veterans with Chronic Back Pain
Rabih Nayfe¹, Matthieu Chansard², Linda S. Hynan³, Eric M. Mortensen⁴ and Una E. Makris⁵, ¹Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ²Clinical Sciences, UT Southwestern Medical Center, Dallas, TX, ³Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX, ⁴UT Southwestern Medical Center, Dallas, TX, ⁵UT Southwestern Medical Center and Dallas VA, Dallas, TX
Background/Purpose: Chronic back pain is the second most common reason for a physician’s visit and results in significant physical and psychosocial consequences in older adults.…

1
2
3
…
5
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].